New Scaffold for Angiogenesis Inhibitors Discovered by Targeted

Subscriber access provided by University of Sussex Library

Letter

New Scaffold for Angiogenesis Inhibitors Discovered by Targeted Chemical Transformations of Wondonin Natural Products Shuai Yu, Jedo Oh, Feng Li, Yongseok Kwon, Hyunkyung Cho, Jongheon Shin, Sang Kook Lee, and Sanghee Kim ACS Med. Chem. Lett., Just Accepted Manuscript • Publication Date (Web): 12 Sep 2017 Downloaded from http://pubs.acs.org on September 12, 2017

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

ACS Medicinal Chemistry Letters is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 7

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

ACS Medicinal Chemistry Letters

New Scaffold for Angiogenesis Inhibitors Discovered by Targeted Chemical Transformations of Wondonin Natural Products Shuai Yu,† Jedo Oh,† Feng Li, Yongseok Kwon, Hyunkyung Cho, Jongheon Shin, Sang Kook Lee,* Sanghee Kim* College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Korea KEYWORDS: Angiogenesis, Diabetic retinopathy, Drug design, VEGF/VEGFR2 pathway, Wondonins ABSTRACT: The structure of wondonin marine natural products was renovated to attain new drug-like scaffolds. Wondonins have novel anti-angiogenic properties without overt cytotoxicity. However, the chemical instability and synthetic complexity of wondonins have hindered their development as a new type of anti-angiogenesis agent. Using a structure-based bioisosterism, the benzodioxole moiety was changed to benzothiazole, and the imidazole moiety was replaced by 1,2,3-triazole. Our efforts resulted in a new scaffold with enhanced anti-angiogenic activity and minimized cytotoxicity. One compound with this scaffold effectively inhibited hyaloid vessel formation in diabetic retinopathy mimic zebrafish model. The biological findings together suggested the potential of the scaffold as a lead structure for development of anti-angiogenic drugs with novel functions and as a probe to elucidate new biological mechanisms associated with angiogenesis.

Nature has provided an immense array of bioactive chemical entities across structurally diverse scaffolds.1 Some scaffolds are suitable for direct employment as templates in the generation of compounds with drug-like properties, but other scaffolds are not directly suitable for use in drug development, mostly due to unfavorable physicochemical properties. In the latter case, transformative structural renovations are desirable to extract new scaffolds that are more relevant for drug discovery.

Figure 1. Chemical structures of wondonins and analogues.

Wondonins and isowondonins (1 and 2, Figure 1) are structurally unique marine alkaloids that were identified from an association of the sponges Poecillatra wondoensis and Jaspis sp.2,3 These marine natural products possess an unusual skeleton with a five-membered acetal ring. Attached vinyl sulfate and histamine moieties distinguish wondonins from other natural products. Wondonins 1 and isowondonins 2

differ in the configuration of the styryl double bond. We previously defined the relative and absolute stereochemistries of isowondonins via the asymmetric synthesis and electronic circular dichroism calculations.4 The family of wondonins has notable anti-angiogenic properties5 by suppressing the expression of HIF-1ɑ and vascular endothelial growth factor (VEGF) in endothelial cells. In contrast to other anti-angiogenesis agents, a remarkable biological property of wondonins is that they inhibit angiogenesis without overt cytotoxicity.2,3,5 Angiogenesis is the formation of new blood vessels from preexisting ones, which occurs under normal physiological conditions such as embryonic vascular development and wound healing.6 Aberrant angiogenesis is observed in disease processes including diabetic ocular neovascularization, duodenal ulcers, arthritis, and cancer.7 VEGF is one of the most important factors regulating angiogenesis.8 VEGF is enriched in the endothelial cells for new blood vessels and plays roles in vascular permeability, vascular network growth, and vessel cell survival.8 Therefore, the modulation of the VEGF-mediated angiogenic pathway is considered an important target in drug discovery programs for diseases associated with the over-activation of angiogenesis.9,10 Several VEGF-signaling pathway inhibitors are on the market for the treatment of cancer or are in clinical trials.9–11 A large array of compounds are also currently in pre-clinical development. Most studies of VEGF pathway inhibitors have focused on the identification of compounds with high inhibitory effects on human umbilical vascular endothelial cell (HUVEC) proliferation that could be used for the treatment of cancer.9–11 In addition to their use as anti-cancer drugs, VEGF pathway inhibitors have been proposed as potential therapeutic agents for obesity and diabetic retinopathy.12-14 However, few drugs that specifically inhibit the pathways for such diseases are available. We conceived that the relevant biological properties of novel anti-angiogenesis agents targeting the VEGF pathway,

ACS Paragon Plus Environment


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

especially for the treatment of diabetic retinopathy, should include minimized cytotoxicity or no cytotoxicity to avoid side effects in normal cells. In this regard, we consider structurally unique wondonins a promising starting point for the generation of a new lead compound. However, the wondonin family presents challenges due to their chemical instability. The five-membered acetal ring and the vinyl sulfate moiety are unstable, particularly under acidic conditions. In our laboratory, wondonins readily decompose unless stored at freezer temperatures and remain free of acid or base contaminants. Another concern is their difficult synthesis. In our total synthesis, installation of the vinyl sulfate and histamine moieties was not trivial.4 In addition, the burdens associated with the introduction of two stereocenters are significant. Therefore, our primary aim in this study was to discover a new scaffold from the structures of wondonins that is chemically stable and easily accessible with drug-like properties. In this study, a series of wondonin analogues were designed, synthesized, and evaluated. Our efforts resulted in structurally distinct drug-like scaffolds with more potent antiangiogenic activity without overt cytotoxicity to HUVECs. As an initial structural modification of wondonins, the imidazole moiety was replaced by its bioisostere, 1,2,3triazole. This replacement was made because the regioselective N-alkylation of a substituted-1H-imidazole is difficult due to the rapid tautomeric equilibrium.4,15 In addition, the preparation of a wide range of suitably substituted-1H-imidazoles is not trivial.16 By contrast, a 1,4disubstituted 1,2,3-triazole moiety can be easily introduced via a Cu(I)-catalyzed azide-alkyne 1,3-dipolar cycloaddition (CuAAC) reaction.17 Given the instability and synthetic difficulty, the vinyl sulfate moiety of wondonins was substituted for a simple ethyl group, which is neither significantly electron donating nor withdrawing. Although ethyl might not be an optimal substituent for activity, it is a good starting point for further optimization due to its unbiased physicochemical properties. Such structural modifications resulted in analogue 3 (Figures 1 and 2). The designed analogue 3 was prepared as a mixture of diastereomers that were inseparable (see Scheme S1 and

Page 2 of 7

synthetic details in the Supporting Information). Its antiangiogenic activity was assessed by measuring its effects on VEGF-induced tube formation and growth of HUVECs in comparison with those of natural wondonin A (1a) (see Figure S1 in the Supporting Information).18 The effect on tube formation was determined by counting the intact tube number under a microscope, and the IC50 of the compound was calculated by comparison with the control group. The effect on cell growth was measured in the MTT assay. As shown in Figure 2, the triazole analogue 3 was 1.5-fold more potent than the parent natural product 1a in the tube formation assay and was nearly as inactive as the parent 1a in inhibiting the growth of HUVECs. Furthermore, analogue 3 did not show overt cytotoxicity against various cancer cell lines (see Table S1 in the Supporting Information), similar to wondonin A. These results suggested that the triazole and ethyl moieties in 3 could serve as bioisosteric replacements for the imidazole and vinyl sulfate moieties in wondonins. The next replacement was implemented in the fivemembered acetal ring. With the aim of eliminating the stereocenter at C1 and endowing stability, the benzodioxole ring of 3 was replaced with several benzo-fused heteroaromatics, including benzofuran, benzothiazole, and benzoxazole (Figures 1 and 2). The benzofuran analogue 4 displayed considerably improved potency in the inhibition of tube formation (Figure 2) and was approximately 7 and 5 times more potent than the natural product 1a and benzodioxole analogue 3, respectively. In contrast to 1a and 3, benzofuran 4 exhibited a moderate inhibitory effect on the VEGF-induced growth of HUVECs. The benzoxazole analogue 5 did not show notable activity against tube formation. By contrast, the benzothiazole analogue 6 was approximately 2 times more potent than the benzofuran analogue 4 and less cytotoxic to cells. Based on the selectivity index of the ratio of the IC50 for tube formation to the IC50 for cell growth, the benzothiazole analogue 6 had more desirable biological properties than the other heteroaromatic analogues. Thus, benzothiazole 6 was used as a new lead scaffold for further structural modification.19


Page 3 of 7

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Figure 2. Chemical structures of wondonin A (1a), analogues 3–12, and sunitinib and measurement of their effects on the VEGF-induced tube formation and cell growth of HUVECs. Tube formation was determined by counting the number of intact tubes after treatment with each compound in the absence or presence of VEGF (50 ng/mL) for 8 h. The value represents the mean IC50 in triplicate experiments against VEGF-induced tube formation by HUVECs. Cell growth was measured by the MTT assay after treatment with each compound in the presence of VEGF (50 ng/mL) for 24 h. The value represents the mean IC50 in triplicate experiments against VEGF-induced cell growth in HUVECs. The fold change was calculated as the ratio of the IC50 values of tube formation and cell growth. For the values of IC50 ± SD, see Table S2 in the Supporting Information.

To assess the importance of the catechol unit in the biological activity of benzothiazole analogue 6, two catecholic hydroxyl groups were replaced with a methoxy group (Figure 2). The methoxy analogue 7 was approximately 2–3 times less potent than the parent 6 both in the tube formation assay and the cell growth inhibition assay, and thus the selectivity index remained nearly unchanged. Because replacement with a methoxy group did not cause a significant decrease in activity, a vicinal dimethoxy-substituted benzene ring was used in further structural modifications instead of the metabolically and chemically vulnerable catechol unit. The next structural modification involved the N,N-dimethyl amino group of 7. Typical results are shown in Figure 2. The inhibitory effects on both tube formation and cell growth were sensitive to amino group modifications. All compounds with different amino groups (8–12) exhibited increased tube formation inhibition together with an increase in cell growth inhibition. However, the degrees of inhibition differed, indicating that these two effects were not correlated. For example, while compound 9, with a cyclopentylamino group, was approximately 8 times more potent than compound 7 in tube formation inhibition and 5 times more potent in cell growth inhibition, compound 12, with a piperidine moiety, was approximately 13 times more potent in tube formation inhibition but showed only a two-fold increase in cell growth inhibition. Of the analogues examined in this study, 12 exhibited the highest selectivity index, up to 75, with pronounced inhibitory activity (IC50 = 0.631 µM) against tube formation. The selectivity index of the typical anti-angiogenic tyrosine kinase inhibitor sunitinib20 was also determined in our evaluation system, although its mechanism of action could differ from those of wondonins and the synthesized analogues. Sunitinib exhibited a much lower selectivity index of 18 compared to compound 12; it showed a similar level of inhibitory potency (IC50 = 0.546 µM) against tube formation as 12 but a 4.8-fold higher inhibitory effect on the cell growth of HUVECs. Further biological studies were performed with compound 12 to understand the molecular mechanisms of the new benzothiazole scaffold. The enhancement of endothelial cell migration and tube formation capacity by VEGF was effectively inhibited by 12 in a concentration-dependent manner (Figures 3A and 3B). Biomarker analysis revealed that treatment of HUVECs with VEGF (50 ng/mL) for 20 min led to the activation of PI3K (p-PI3K), AKT (p-AKT) and eNOS (p-eNOS), whereas pretreatment with 12 for 30 min significantly suppressed the activation processes in endothelial cells (Figure 3C). In addition, the levels of VEGFR2 (pVEGFR2) activated by VEGF were also suppressed by 12, which subsequently inhibited the activation of SRC (pSRC)/FAK (p-FAK) in VEGF-stimulated HUVECs. The phosphorylation of VEGFR2 (Tyr1175) affects the activation of PI3K signaling, and this event leads to an increase in vascular permeability.21 In the VEGF signaling pathway, SRC kinases are downstream of VEGFR2 and regulate vascular

permeability and angiogenesis.22 The activation of FAK is also an important contributor to markedly involved in endothelial cell migration, proliferation and adherens junction integrity.23 Therefore, the present data suggest that the inhibition of cell migration and neovascular tube formation by compound 12 is partly associated with modulation of the signaling axis of VEGFR2-mediated PI3K/AKT/eNOS and the SRC/FAK signaling pathway in HUVECs. Recent findings suggest the existence of cross-activation between beta-3-integrin and VEGFR-2 during angiogenesis.24,25 In particular, integrin is associated with stimulation of the migration of endothelial cells. Although we did not directly detect the effect of wondonin analogues on integrin expression, we found that SRC/FAK activation, which is downstream of the integrin signaling pathway and correlated with cell migration, was suppressed by compound 12. This finding suggests that compound 12 is also able to affect integrin signaling indirectly. To further determine whether compound 12 directly affects the activity of kinases that are closely associated with angiogenic processes, compound 12 was evaluated at 10 µM using KINOMEscanTM (DiscoverX Co., Fremont, CA, USA) against a panel of 30 kinases, including VEGFR2. Kinase activity was determined based on the binding capacity between the each kinase and the corresponding ligand. Compound 12 did not significantly inhibit the kinase activities tested (see Table S3 in the Supporting Information) and weakly inhibited only three kinases, namely CSNK1A1, PRKCl, and MEK1 (over 40% inhibition at 10 µM). Therefore, the anti-angiogenic activity of compound 12 might be more relevant in the regulation of VEGF/VEGFR2 axis suppression than in the direct inhibition of angiogenesisassociated kinase activity. Since diabetic retinopathy (DR) is associated with the angiogenic processes,26 we evaluated the effects of compound 12 on neovascular formation in a DR-mimic animal model. In general, DR leads to progressive vascular occlusions, ultimately resulting in blindness with pericyte loss and vessel thickening.27 DR also increases vascular permeability, which leads to macula edema.28 Zebrafish larvae treated with high levels of glucose (HG) were employed as a mimic of mammalian DR models.29 Transgenic zebrafish (flk:EGFP) embryos (3 dpf) were treated with 130 mM glucose for 3 days to induced DR-mimic hyaloid vessels in the larval eye lenses. As shown in Figure 3D, HG-treated zebrafish larvae exhibited significantly increased hyaloid vessel diameters in isolated eye lenses. However, treatment with 12 effectively suppressed the increase in hyaloid vessel diameters induced by HG in a concentration-dependent manner.30 In particular, treatment with 2.5 µM compound 12 markedly reduced the hyaloid vessel diameters in the optic disc area. These results suggest that the reduction in HG-induced hyaloid vessel diameters by 12 might also be associated with anti-angiogenic activity in the in vivo animal model.



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 4 of 7

Figure 3. Anti-angiogenic activities of 12. A, A-1) Inhibition of vascular tube formation in HUVECs by compound 12. The capillary structures were photographed, and the total tube length was quantified. The length of the capillary tubes formed were compared with that obtained for the VEGF-treated control groups. B, B-1) Inhibition of cell migration in HUVECs by compound 12. The migrated cells were counted and compared with the VEGF-treated control groups. C) Effects of compound 12 on the VEGFR2 signaling pathway. The cells were treated with various concentrations of compound 12 for 30 min and then stimulated with VEGF (50 ng/mL) for 20 min. β-actin was used as a loading control. D) Inhibition of hyaloid vessels in HG-treated zebrafish larvae by compound 12. The hyaloid vessel diameters were measured at a position near the optic disc (red circle) using ImageJ software (scale bar = 50 µm). Quantification of the number of primary vessel branches compared with that in the HG-treated control groups. A, B, D) P values were calculated by ANOVA using Tukey’s test (# # # P < 0.001, # # P < 0.01; *P < 0.05, **P < 0.01; ***P < 0.001, n=3)

To evaluate pharmaceutical properties of compound 12, the aqueous solubility, permeability, plasma stability, and metabolic stability were examined (Table 1). A notable property of 12 is its high plasma stability that is important for the achievement of in vivo activity. Compound 12 showed plasma stability of 95% remaining intact after 30 min incubation with human plasma. In the metabolic stability study using human liver microsomes, a modest microsomal stability was observed. Compound 12 exhibited high MDCK cell permeability but low aqueous solubility (Biopharmaceutics Classification System Class 2), probably due to its high lipophilicity. Our theoretical calculations indicated that the physicochemical properties of 12 were in compliance with Lipinski’s rule of five and Veber’s rule for druglikeness except a logP value (5.955) (see Table S4 in the Supporting Information). Functional group modifications of 12 are in progress in our laboratory, such as replacement of a methoxy group with a more polar bioisosteric moiety, to improve solubility and metabolic stability by lowering the lipophilicity. Table 1. Preliminary ADME Study of 12 pKa

solub (mM)a

MDCK Papp,A‑B (10-6 cm/s)b

plasma stability (%)c

microsomal stability (%)d

9.24

0.024

11

95

31

Measured by the CheqSol method at 25 °C. bApparent permeability coefficients (Papp,A‑B) across MDCK cell monolayers. cThe

percentage of parent compound remaining after 30 min incubation in human plasma. dThe percentage of parent compound remaining after 30 min incubation in human liver microsomes.

In summary, using the structure of wondonin marine natural products, we created a novel lead scaffold for the development of a new type of anti-angiogenesis agent that possesses potent anti-angiogenic activity with minimized cytotoxicity to avoid side effects. The analogues with benzothiazole and 1,2,3triazole rings, in place of benzodioxole and imidazole moieties, respectively, displayed the desired biological properties. The representative compound 12, which was more easily synthesized than the parent natural product, exhibited an excellent selectivity index with pronounced inhibitory activity. The in vivo anti-angiogenic activity was also assessed using DR-mimic zebrafish, which demonstrated the high potential of the new scaffold for the treatment of diseases requiring antiangiogenesis agents with minimized cytotoxicity. The precise target of this new class of compounds remains unclear. Further elucidation of the specific molecular target of compound 12 are in progress. In addition, we are currently investigating the structure-activity relationship in this series of compounds in more detail to elucidate the minimal pharmacophore required for the selectivity between anti-angiogenic activity and cytotoxicity to HUVECs. The results of these efforts will be reported in due course.

a

ASSOCIATED CONTENT


Page 5 of 7

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Supporting Information. Synthetic Scheme S1 and S2, experimental procedures and spectroscopic data for all new compounds, supplementary Tables S1–S4, Figure S1 and S2, and HPLC analysis of biologically tested compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION Corresponding Author *S.K.L., E-mail: [email protected]. *S.K., E-mail: [email protected].

ORCID Sang Kook Lee: 0000-0002-4306-7024 Sanghee Kim: 0000-0001-9125-9541

Author Contributions †

S.Y. and J.O. contributed equally to this work. All authors have given approval to the final version of the manuscript.

Notes The authors declare no conflict of interest.

Funding This work was supported by the Mid-Career Researcher Program (NRF-2016R1A2A1A05005375) of the National Research Foundation (NRF) grant funded by the Korea government (MSIP). This work was also supported by NRF (Grant 20090083533) grant funded by the Korean Government (MEST).

ABBREVIATIONS ADME, absorption distribution metabolism excretion; AKT, protein kinase B; CSNK1A1, casein kinase 1 isoform alpha; EGM-2, endothelial cell growth medium-2; eNOS, endothelial NOS; FAK, focal adhesion kinase; FBS, fetal bovine serum; HIF1ɑ, hypoxia inducible factor 1-alpha; MDCK, madin-darby canine kidney; MEK1, mitogen-activated protein kinase 1; MTT, 3-(4,5Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PI3K, phosphoinositide 3-kinase; PRKCl, protein kinase C iota; PVDF, polyvinylidene difluoride; qPCR, quantitative PCR; VEGFR, vascular endothelial growth factor receptor.

REFERENCES (1) Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 2012, 75, 311‒335. (2) Shin, J.; Rho, J.-R.; Seo, Y.; Lee, H.-S.; Cho, K. W.; Kwon, H. J.; Sim, C. J. Wondonins A and B, new bis(dihydroxystyryl)imidazoles from a two-sponge association. Tetrahedron Lett. 2001, 42, 1965–1968. (3) Chang, Y. H.; Shin, D.; Na, Z.; Lee, H.-S.; Kim, D.-D.; Oh, K. B.; Shin, J. Dihydroxystyrene metabolites from an association of the sponges Poecillastra wondoensis and Jaspis sp. J. Nat. Prod. 2008, 71, 779–783. (4) Yu, S.; Li, F.; Jeon, H.; Lee, S.; Shin, J.; Kim, S. Total syntheses of isowondonins based on a biosynthetic pathway. Org. Lett. 2016, 18, 2986–2989. (5) Jun, H.-O.; Kim, Y.; Kwon, Y.-W.; Hong, S.-S.; Kim, K.-W.; Shin, J.; Kim, T.-Y. Wondonin, a novel compound, inhibits hypoxiainduced angiogenesis through hypoxia-inducible factor 1 alpha. FEBS Lett. 2007, 581, 4977–4982. (6) Eming, S. A.; Brachvogel, B.; Odorisio, T.; Koch, M. Regulation of angiogenesis: wound healing as a model. Prog. Histochem. Cytochem. 2007, 42, 115–170. (7) Carmeliet, P. Angiogenesis in health and disease. Nat. Med. 2003, 9, 653–660. (8) Hoeben, A.; Landuyt, B.; Highley, M. S.; Wildiers, H.; Van Oosterom, A. T.; De Bruijn, E. A. Vascular endothelial growth factor and angiogenesis. Pharmacol. Rev. 2004, 56, 549–580.

(9) Ferrara, N.; Kerbel, R. S. Angiogenesis as a therapeutic target. Nature 2005, 438, 967–974. (10) Carmeliet, P.; Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473, 298–307. (11) Musumeci, F.; Radi, M.; Brullo, C.; Schenone, S. Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors. J. Med. Chem. 2012, 55, 10797–10822. (12) Gariano, R. F.; Gardner, T. W. Retinal angiogenesis in development and disease. Nature 2005, 438, 960–966. (13) Salam, A.; Mathew, R.; Sivaprasad, S. Treatment of proliferative diabetic retinopathy with anti-VEGF agents. Acta. Ophthalmol. 2011, 89, 405–411. (14) Park, B. Y.; Lee, H.; Woo, S.; Yoon, M.; Kim, J.; Hong, Y.; Lee, H. S.; Park, E. H.; Hahm, J. C.; Kim, J. W.; Shin, S. S.; Kim, M. Y.; Yoon, M. Reduction of adipose tissue mass by the angiogenesis inhibitor ALS-L1023 from Melissa officinalis. PLoS One 2015, 10, e0141612. (15) Allin, S. M.; Bowman, W. R.; Elsegood, M. R. J.; McKee, V.; Karim, R.; Rahman, S. S. Synthetic applications of aryl radical building blocks for cyclisation onto azoles. Tetrahedron 2005, 61, 2689– 2696. (16) Kamijo, S.; Yamamoto, Y. Recent progress in the catalytic synthesis of imidazoles. Chem. Asian J. 2007, 2, 568–578. (17) Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Click chemistry: diverse chemical function from a few good reactions. Angew. Chem. Int. Ed. 2001, 40, 2004–2021. (18) Wondonin suppresses VEGF expression under hypoxia conditions.5 In the present study, the analogues were evaluated using a VEGF-induced angiogenesis model rather than under hypoxia conditions because we hypothesized that evaluation under hypoxia conditions is more relevant to cancer. (19) Similarly to wondonin, compound 6 suppresses HIF-1α and downstream targets under hypoxia conditions (see Figure S2 in the Supporting Information). These data suggest that the mechanisms involved in the anti-angiogenic activity of wondonin and its analogues are similar. (20) Roskoski Jr, R. Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem. Biophys. Res. Commun. 2007, 356, 323–328. (21) Olsson, A. K.; Dimberg, A.; Kreuger, J.; Claesson-Welsh, L. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 2006, 7, 359–371. (22) Eliceiri, B. P.; Paul, R.; Schwartzberg, P. L.; Hood, J. D.; Leng, J.; Cheresh, D. A. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell 1999, 4, 915–924. (23) Lechertier, T.; Hodivala-Dilke, K. Focal adhesion kinase and tumour angiogenesis. J. Pathol. 2012, 226, 404–412. (24) Mahabeleshwar, G. H.; Feng, W.; Reddy, K.; Plow, E. F.; Byzova, T. V. Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ. Res. 2007, 101, 570–580. (25) Somanath, P. R.; Malinin, N. L.; Byzova, T. V. Cooperation between integrin alphavbeta3 and VEGFR2 in angiogenesis. Angiogenesis 2009, 12, 177–185. (26) Noma, H.; Funatsu, H.; Yamashita, H.; Kitano, S.; Mishima, H. K.; Hori, S. Regulation of angiogenesis in diabetic retinopathy: possible balance between vascular endothelial growth factor and endostatin. Arch. Ophthalmol. 2002, 120, 1075–1080. (27) Ciulla, T. A.; Amador, A. G.; Zinman, B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003, 26, 2653–2664. (28) Bergers, G.; Song, S. The role of pericytes in blood-vessel formation and maintenance. Neuro. Oncol. 2005, 7, 452–464. (29) Jung, S. H.; Kim, Y. S.; Lee, Y. R.; Kim, J. S. High glucoseinduced changes in hyaloid-retinal vessels during early ocular development of zebrafish: a short-term animal model of diabetic retinopathy. Br. J. Pharmacol. 2016, 173, 15–26. (30) No significant toxicity was observed in any of the embryos treated with 12.



Page 6 of 7


6

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 7 of 7

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


For Table of Contents Use Only

New Scaffold for Angiogenesis Inhibitors Discovered by Targeted Chemical Transformations of Wondonin Natural Products Shuai Yu,† Jedo Oh,† Feng Li, Yongseok Kwon, Hyunkyung Cho, Jongheon Shin, Sang Kook Lee,* Sanghee Kim*


7

New Scaffold for Angiogenesis Inhibitors Discovered by Targeted

Recommend Documents